医药行业周报：优时比Bimzelx获FDA批准，用于治疗HS

Investment Rating - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as Neutral [2][10]. Core Insights - The pharmaceutical sector experienced a decline of 0.35% on November 21, 2024, underperforming the CSI 300 index by 0.44 percentage points, ranking 27th among 31 sub-industries in the Shenwan classification. Blood products (+0.18%) and vaccines (-0.10%) performed relatively well, while medical devices (-1.23%) and offline pharmacies (-1.07%) lagged behind [4][5]. - UCB announced that the FDA approved Bimzelx (bimekizumab) for treating moderate to severe hidradenitis suppurativa (HS) in adults. This drug is a humanized IgG1 monoclonal antibody that selectively binds to IL-17A, IL-17F, and IL-17AF cytokines [5]. Summary by Sections Market Performance - On November 21, 2024, the pharmaceutical sector's performance was -0.35%, underperforming the CSI 300 index by 0.44 percentage points. The sector ranked 27th among 31 sub-industries, with blood products showing a positive change of +0.18% [4]. Industry News - UCB's Bimzelx received FDA approval for treating HS, marking its second approval after being cleared for moderate to severe plaque psoriasis in October 2023 [5]. - Various companies, including Yuandong Bio and Buchang Pharma, received approvals for new drugs from the National Medical Products Administration, indicating ongoing regulatory progress in the pharmaceutical sector [5].